JP2019501151A - 抗デスレセプター抗体およびその使用方法 - Google Patents

抗デスレセプター抗体およびその使用方法 Download PDF

Info

Publication number
JP2019501151A
JP2019501151A JP2018529176A JP2018529176A JP2019501151A JP 2019501151 A JP2019501151 A JP 2019501151A JP 2018529176 A JP2018529176 A JP 2018529176A JP 2018529176 A JP2018529176 A JP 2018529176A JP 2019501151 A JP2019501151 A JP 2019501151A
Authority
JP
Japan
Prior art keywords
antibody
mutation
igg1
molar ratio
fas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018529176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501151A5 (show.php
Inventor
フランク ベアースケンズ
フランク ベアースケンズ
マリジュ オーバーダイク
マリジュ オーバーダイク
ジョン ロブ デ
ジョン ロブ デ
デビッド サテン
デビッド サテン
クリスティン ストルマン
クリスティン ストルマン
ジェニン シュールマン
ジェニン シュールマン
ポール パレン
ポール パレン
Original Assignee
ゲンマブ ビー．ブイ．
ゲンマブ ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゲンマブ ビー．ブイ．, ゲンマブ ビー．ブイ． filed Critical ゲンマブ ビー．ブイ．
Publication of JP2019501151A publication Critical patent/JP2019501151A/ja
Publication of JP2019501151A5 publication Critical patent/JP2019501151A5/ja
Priority to JP2022188988A priority Critical patent/JP7679347B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2018529176A 2015-12-01 2016-12-01 抗デスレセプター抗体およびその使用方法 Withdrawn JP2019501151A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022188988A JP7679347B2 (ja) 2015-12-01 2022-11-28 抗デスレセプター抗体およびその使用方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
DKPA201500771 2015-12-01
DKPA201500771 2015-12-01
DKPA201500788 2015-12-07
DKPA201500787 2015-12-07
DKPA201500787 2015-12-07
DKPA201500788 2015-12-07
DKPA201600702 2016-11-10
DKPA201600701 2016-11-10
DKPA201600701 2016-11-10
DKPA201600702 2016-11-10
PCT/EP2016/079517 WO2017093447A1 (en) 2015-12-01 2016-12-01 Anti-death receptor antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022188988A Division JP7679347B2 (ja) 2015-12-01 2022-11-28 抗デスレセプター抗体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2019501151A true JP2019501151A (ja) 2019-01-17
JP2019501151A5 JP2019501151A5 (show.php) 2020-01-16

Family

ID=58796495

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018529176A Withdrawn JP2019501151A (ja) 2015-12-01 2016-12-01 抗デスレセプター抗体およびその使用方法
JP2018529087A Active JP7254515B2 (ja) 2015-12-01 2016-12-01 抗ｄｒ５抗体およびその使用方法
JP2022188988A Active JP7679347B2 (ja) 2015-12-01 2022-11-28 抗デスレセプター抗体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018529087A Active JP7254515B2 (ja) 2015-12-01 2016-12-01 抗ｄｒ５抗体およびその使用方法
JP2022188988A Active JP7679347B2 (ja) 2015-12-01 2022-11-28 抗デスレセプター抗体およびその使用方法

Country Status (15)

Country Link
US (5) US20190202926A1 (show.php)
EP (4) EP4467648A3 (show.php)
JP (3) JP2019501151A (show.php)
KR (1) KR20180098567A (show.php)
CN (2) CN109476737A (show.php)
AU (2) AU2016363770A1 (show.php)
BR (2) BR112018011100A2 (show.php)
CA (2) CA3007033A1 (show.php)
IL (1) IL259713B1 (show.php)
MA (1) MA43365A (show.php)
MX (1) MX2018006333A (show.php)
SG (1) SG11201803956UA (show.php)
UA (1) UA126897C2 (show.php)
WO (2) WO2017093447A1 (show.php)
ZA (1) ZA201803079B (show.php)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057881A1 (en) * 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US20190202926A1 (en) 2015-12-01 2019-07-04 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
CN111328335A (zh) * 2017-06-07 2020-06-23 根马布私人有限公司 基于突变igg六聚体的治疗性抗体
MA50102A (fr) * 2017-11-14 2020-07-15 Univ Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
CN109957020A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
JP2021510740A (ja) 2018-01-24 2021-04-30 ゲンマブ ビー．ブイ． ポリペプチド変種およびそれらの用途
WO2019211472A1 (en) 2018-05-03 2019-11-07 Genmab B.V. Antibody variant combinations and uses thereof
PE20211858A1 (es) * 2018-07-13 2021-09-21 Genmab As Variantes de anticuerpos anti-cd38 y sus usos
CN112638946A (zh) 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
JP2022531894A (ja) 2019-05-09 2022-07-12 ゲンマブ ビー．ブイ． がんの処置において使用するための抗ｄｒ５抗体の組み合わせの投与レジメン
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof
US20230174660A1 (en) * 2020-05-12 2023-06-08 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
CN111778333B (zh) * 2020-07-03 2022-11-18 东莞市滨海湾中心医院 测定edar表达水平的试剂的应用和试剂盒
EP4185388A1 (en) 2020-07-23 2023-05-31 Genmab B.V. A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
EP4214239A4 (en) * 2020-10-14 2025-07-09 Univ Virginia Patent Foundation COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS
CN112915211B (zh) * 2021-02-07 2022-05-06 成都中医药大学 一种pd-l1靶向肽药物偶联物及其合成方法和应用
US20250376532A1 (en) * 2021-08-20 2025-12-11 University Of Virginia Patent Foundation Strategy for highly superior dr5 activation including in tumors and cancers
AU2024271605A1 (en) * 2023-05-12 2025-11-13 BioNTech SE Antibodies capable of binding to ox40, variants thereof and uses thereof
GB202315963D0 (en) * 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
WO2025160152A2 (en) * 2024-01-23 2025-07-31 The Regents Of The University Of California Fas antibody and its use in treating cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520788A (ja) * 2011-07-06 2014-08-25 ゲンマブ ビー．ブイ． 抗体変異体およびその使用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US761218A (en) 1899-10-05 1904-05-31 U S Standard Voting Machine Co Register or counter.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6469144B1 (en) 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
AU6250098A (en) 1997-01-28 1998-08-18 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
WO1999036535A1 (en) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
EP1150918B1 (en) 1999-02-03 2004-09-15 Biosante Pharmaceuticals, Inc. Method of manufacturing therapeutic calcium phosphate particles
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
ATE330972T1 (de) 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
US6444640B1 (en) 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
KR100942393B1 (ko) 2001-05-25 2010-02-17 휴먼 게놈 사이언시즈, 인코포레이티드 Ｔｒａｉｌ 수용체에 면역특이적으로 결합하는 항체
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
JP4663232B2 (ja) 2001-11-01 2011-04-06 ザ ユーエービー リサーチ ファウンデーション 腫瘍壊死因子関連アポトーシス誘導リガンドレセプターに対して選択的な抗体と他の治療剤の組み合わせ
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
US20050266008A1 (en) 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
PL2213683T3 (pl) * 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
JP5214252B2 (ja) 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド ヒト化ｌ２４３抗体
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
PL2158221T3 (pl) 2007-06-21 2019-02-28 Macrogenics, Inc. Kowalencyjne diaciała i ich zastosowania
TW200904072A (en) 2007-07-05 2009-01-16 Ic Plus Corp System and method for generating interrupt
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
AU2009335798B2 (en) 2008-12-19 2014-11-27 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010138725A1 (en) 2009-05-28 2010-12-02 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
LT2560993T (lt) 2010-04-20 2024-10-10 Genmab A/S Baltymai, kurių sudėtyje yra heterodimerinio antikūno fc, ir jų gamybos būdai
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
WO2012025525A1 (en) 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
JP5918143B2 (ja) * 2010-10-29 2016-05-18 第一三共株式会社 新規抗ｄｒ５抗体
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102654260B (zh) 2011-09-29 2014-09-03 北京京东方光电科技有限公司 一种背光源和液晶显示器
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
AU2013285355A1 (en) * 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
KR20220156667A (ko) 2013-01-10 2022-11-25 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
EP3048116A1 (en) * 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
US20190202926A1 (en) 2015-12-01 2019-07-04 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
CA3041988A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
IL268593B2 (en) 2017-02-10 2025-05-01 Genmab Bv Polypeptides and antibodies having increased cdc and/or agonistic activity and their uses in medicine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520788A (ja) * 2011-07-06 2014-08-25 ゲンマブ ビー．ブイ． 抗体変異体およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOGENE, vol. 25, JPN6020039884, 2006, pages 5145 - 5154, ISSN: 0004836470 *

Also Published As

Publication number Publication date
US20210324096A1 (en) 2021-10-21
CN109476737A (zh) 2019-03-15
IL259713B1 (en) 2025-11-01
IL259713A (en) 2018-07-31
EP3383905A1 (en) 2018-10-10
WO2017093448A1 (en) 2017-06-08
JP7679347B2 (ja) 2025-05-19
CN108884158A (zh) 2018-11-23
UA126897C2 (uk) 2023-02-22
JP2019500869A (ja) 2019-01-17
AU2024200261A1 (en) 2024-02-01
WO2017093447A1 (en) 2017-06-08
US20190315877A1 (en) 2019-10-17
AU2016363770A1 (en) 2018-06-28
EP4467648A3 (en) 2025-02-26
US20190202926A1 (en) 2019-07-04
MX2018006333A (es) 2018-08-01
CA3007033A1 (en) 2017-06-08
EP3383906A1 (en) 2018-10-10
NZ743316A (en) 2023-12-22
JP2023022186A (ja) 2023-02-14
CA3007031A1 (en) 2017-06-08
EP4464333A3 (en) 2025-05-14
MA43365A (fr) 2018-10-10
US20220411522A1 (en) 2022-12-29
ZA201803079B (en) 2023-12-20
BR112018011058A2 (en) 2018-11-21
US12247080B2 (en) 2025-03-11
KR20180098567A (ko) 2018-09-04
EP4467648A2 (en) 2024-11-27
US10882913B2 (en) 2021-01-05
EP4464333A2 (en) 2024-11-20
US20190144554A1 (en) 2019-05-16
SG11201803956UA (en) 2018-06-28
JP7254515B2 (ja) 2023-04-10
BR112018011100A2 (en) 2018-12-04

Similar Documents

Publication Publication Date Title
JP7679347B2 (ja) 抗デスレセプター抗体およびその使用方法
JP7577446B2 (ja) ポリペプチドバリアントおよびそれらの使用
US12338289B2 (en) Antibody variant combinations and uses thereof
JP2023145720A (ja) 変異ＩｇＧ六量体に基づく治療用抗体
CA3193914A1 (en) Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
HK40118860A (en) Anti-death receptor antibodies and methods of use thereof
KR20220103105A (ko) 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법
HK40120020A (en) Anti-dr5 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201022

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210421

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220727

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221128

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20221208

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221208

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104